Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

The Business Research Company The Business Research Company's Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Global Market Report. Tuesday, 02 January 2024 12:17 GMT.

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...

GLP-1 agonists, or glucagon-like peptide-1 agonists, function by mimicking the action of a natural hormone in the body that helps regulate blood sugar levels and digestion. Originally developed for ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Martin Vollmer, biopharma program manager at Agilent Technologies, spoke to LCGC International about the evolving importance of glucagon-like peptide-1 (GLP-1) therapeutics and the challenges they ...

A new review suggests that tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms that could help reduce the ...

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...